Nomination Committee appointed for 2010-2011

Nomination Committee appointed for 2010-2011

Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical
company focused on infectious diseases, today announces that a new
Nomination Committee has been appointed consisting of; Maria Wikström,
Länsförsäkringar Fondförvaltning AB, Bo Öberg, representing A
shareholders, Frank Larsson, Handelsbanken Kapitalförvaltning and Göran
Pettersson, Chairman of the Board. 

Pursuant to an AGM resolution, the Nomination Committee shall consist of
the Chairman of the Board and three shareholder representatives, for
which the three largest shareholders as of the end of the third quarter
2010 shall first be invited. 

For additional information, please contact;
Rein Piir, CFO & VP Investor Relations; cell phone +46 708 537 292.
 

About Medivir
Medivir is a research-based specialty pharmaceutical company focused on
the development of high-value treatments for infectious diseases.
Medivir has world class expertise in polymerase and protease drug
targets and drug development. Medivir has a strong R&D portfolio and has
recently launched its first product Xerese™/Xerclear®. Medivir's key
pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical
development for Hepatitis C and is partnered with Tibotec
Pharmaceuticals. 

Xerese™/Xerclear® is an innovative treatment for cold sores, which has
been approved in both the US and Europe. It is partnered with GSK to be
sold OTC in Europe and Russia and with Meda in North America. Medivir
has retained the Rx rights for Xerclear® in Sweden and Finland.
 

For more information on Medivir, please see the company website:
www.medivir.se (http://www.medivir.se/)